Casey Jamison
Women's Health · Crossroads, TXNPI 1043614233
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 47.4% of the total. 2025 is the largest year on record at $594, 2.4 times the $244 reported in 2021. Among women's health clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$431
- Lilly USA, LLC$230
- Pfizer$157
- Astellas Pharma US Inc$142
- Acella Pharmaceuticals, LLC$61
- plus $175 from 8 others
What the payments were for
- Food & beverage$2,20597%
- Education$663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 75 | $1,076 |
| Novo Nordisk | 26 | $431 |
| Lilly USA, LLC | 14 | $230 |
| Pfizer | 7 | $157 |
| Astellas Pharma US Inc | 5 | $142 |
| Acella Pharmaceuticals, LLC | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Corcept Therapeutics | 1 | $27 |
| Bayer | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $14 |
How this compares
$2,271 in reported general payments places this provider in the 90th percentile of 609 women's health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 13 | $448 |
| Bupropion XlBupropion Hcl | 14 | $165 |
| Atorvastatin Calcium | 23 | $161 |
| Losartan Potassium | 16 | $159 |
| Metformin Hcl | 11 | $153 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 16 | $137 |
| Levothyroxine Sodium | 23 | $128 |
| Trazodone Hcl | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Other women's health in Crossroads
- Evelyn TingGrapevine$89K
- Christina TrumanWaco$70K
- Kayla CastanedaEl Paso$53K
- Shelagh LarsonFort Worth$43K
- Amanda ArmondAustin$17K
- Joann St PierreHouston$15K
- Christina BlancoEl Paso$14K
- Ricshonda MilburnGalveston$13K
- Sandra EastlingLubbock$12K
- Lori WinkHouston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.